Data from the National Vital Statistics System, a collaboration between the National Center for Health Statistics of the U.S. Department of Health and Human Services and each US state, provides the best estimate of suicides.
From 1999-2010, the suicide rate in the US population among males was 19.4 per 100,000, compared to 4.9 per 100,000 in females.
Based on the most recent data available, in fiscal year 2009, the suicide rate among male Veteran VA users was 38.3 per 100,000, compared to 12.8 per 100,000 in females.
An estimated 8% of Americans − 24.4 million people − have PTSD at any given time. That is equal to the total population of Texas.
An estimated one out of every nine women develops PTSD, making them about twice as likely as men.
PTSD affects about 7.7 million American adults in a given year, though the disorder can develop at any age including childhood. Symptoms include strong and unwanted memories of the event, bad dreams, emotional numbness, intense guilt or worry, angry outbursts, feeling “on edge,” and avoiding thoughts and situations that are reminders of the trauma.
In August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the FDA has designated MDMA as a “Breakthrough Therapy.”
This means that “preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies,” as per the FDA. Essentially, the evidence of multiple peer-reviewed clinical trials supports the use of this drug in treating PTSD.
New research using human minibrains has revealed that a hallucinogenic compound known as 5-MeO-DMT triggers changes in neuronal signaling pathways associated with inflammation, neural plasticity, and neurodegeneration. The discovery is critically important now, because various studies have found benefits from psychedelic use, but have been unable to parse out how and why these compounds have produced specific positive effects.